Cahyo Wibisono Nugroho1,2, Satriyo Dwi Suryantoro1,2, Yuliasih Yuliasih1, Alfian Nur Rosyid2,3, Tri Pudy Asmarawati1,2, Lucky Andrianto2,4, Herley Windo Setiawan2,3, Bagus Aulia Mahdi1, Choirina Windradi1, Esthiningrum Dewi Agustin5, Jonny Karunia Fajar6. 1. Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia. 2. Universitas Airlangga Hospital, Surabaya, East Java, 60115, Indonesia. 3. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia. 4. Department of Anesthesiology and Reanimation, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia. 5. Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia. 6. Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, 65145, Indonesia.
Abstract
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods: We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published from March to October 2020 to evaluate optimal use and baseline criteria for administration of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with confirmed SARS-CoV-2 infection, treated with tocilizumab and compared with the standard of care (SOC) was included in this study. We conducted a systematic review to find data about the risks and benefits of tocilizumab and outcomes from different baseline criteria for administration of tocilizumab as a treatment for severe and critically ill COVID-19 patients. Results: A total of 26 studies, consisting of 23 retrospective studies, one prospective study, and two randomised controlled trials with 2112 patients enrolled in the tocilizumab group and 6160 patients in the SOC group, were included in this meta-analysis. Compared to the SOC, tocilizumab showed benefits for all-cause mortality events and a shorter time until death after first intervention but showed no difference in hospital length of stay. Upon subgroup analysis, tocilizumab showed fewer all-cause mortality events when CRP level ≥100 mg/L, P/F ratio 200-300 mmHg, and P/F ratio <200 mmHg. However, tocilizumab showed a longer length of stay when CRP <100 mg/L than the SOC. Conclusion: This meta-analysis demonstrated that tocilizumab has a positive effect on all-cause mortality. It should be cautiously administrated for optimal results and tailored to the patient's eligibility criteria. Copyright:
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab may provide clinical benefits for cytokine release syndrome in COVID-19patients. Methods: We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published from March to October 2020 to evaluate optimal use and baseline criteria for administration of tocilizumab in severe and critically illCOVID-19patients. Research involving patients with confirmed SARS-CoV-2 infection, treated with tocilizumab and compared with the standard of care (SOC) was included in this study. We conducted a systematic review to find data about the risks and benefits of tocilizumab and outcomes from different baseline criteria for administration of tocilizumab as a treatment for severe and critically illCOVID-19patients. Results: A total of 26 studies, consisting of 23 retrospective studies, one prospective study, and two randomised controlled trials with 2112 patients enrolled in the tocilizumab group and 6160 patients in the SOC group, were included in this meta-analysis. Compared to the SOC, tocilizumab showed benefits for all-cause mortality events and a shorter time until death after first intervention but showed no difference in hospital length of stay. Upon subgroup analysis, tocilizumab showed fewer all-cause mortality events when CRP level ≥100 mg/L, P/F ratio 200-300 mmHg, and P/F ratio <200 mmHg. However, tocilizumab showed a longer length of stay when CRP <100 mg/L than the SOC. Conclusion: This meta-analysis demonstrated that tocilizumab has a positive effect on all-cause mortality. It should be cautiously administrated for optimal results and tailored to the patient's eligibility criteria. Copyright:
Authors: Pradeesh Sivapalan; Charlotte Suppli Ulrik; Therese Sophie Lapperre; Rasmus Dahlin Bojesen; Josefin Eklöf; Andrea Browatzki; Jon Torgny Wilcke; Vibeke Gottlieb; Kjell Erik Julius Håkansson; Casper Tidemandsen; Oliver Tupper; Howraman Meteran; Christina Bergsøe; Eva Brøndum; Uffe Bødtger; Daniel Bech Rasmussen; Sidse Graff Jensen; Lars Pedersen; Alexander Jordan; Helene Priemé; Christian Søborg; Ida E Steffensen; Dorthe Høgsberg; Tobias Wirenfeldt Klausen; Martin Steen Frydland; Peter Lange; Asger Sverrild; Muhzda Ghanizada; Filip K Knop; Tor Biering-Sørensen; Jens D Lundgren; Jens-Ulrik Stæhr Jensen Journal: Eur Respir J Date: 2022-01-06 Impact factor: 16.671
Authors: Anna Lebedeva; Ivan Molodtsov; Alexandra Anisimova; Anastasia Berestovskaya; Oleg Dukhin; Antonina Elizarova; Wendy Fitzgerald; Darya Fomina; Kseniya Glebova; Oxana Ivanova; Anna Kalinskaya; Anastasia Lebedeva; Maryana Lysenko; Elena Maryukhnich; Elena Misyurina; Denis Protsenko; Alexander Rosin; Olga Sapozhnikova; Denis Sokorev; Alexander Shpektor; Daria Vorobyeva; Elena Vasilieva; Leonid Margolis Journal: Int J Mol Sci Date: 2022-07-19 Impact factor: 6.208